CHRS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Coherus Oncology Inc (CHRS) is not a strong buy for a beginner, long-term investor at this moment. While the stock shows some positive technical momentum and has a bullish analyst rating with a high price target, the company's financial performance is weak, with declining net income and EPS. Additionally, there are no recent news catalysts or significant trading trends to support a strong buy decision. Given the user's preference for long-term investment, it may be better to wait for clearer financial improvements or stronger catalysts before considering an entry.
The technical indicators suggest a bullish trend with MACD positively expanding, RSI neutral at 78.908, and bullish moving averages (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance levels, with R1 at 1.904 and R2 at 1.992.
Analyst coverage initiated with an Outperform rating and a $10 price target, citing promising clinical readouts and high-potential early-stage opportunities.
Weak financial performance with declining net income (-25.75% YoY) and EPS (-29.55% YoY). No recent news or significant trading trends to act as catalysts.
In Q4 2025, revenue increased by 64.85% YoY to $12.75M, but net income dropped by 25.75% YoY to -$37.64M, and EPS declined by 29.55% YoY to -0.31. Gross margin improved to 68.27%, up 5.94% YoY.
Oppenheimer initiated coverage with an Outperform rating and a $10 price target, citing upcoming clinical readouts and promising drug pipeline opportunities.
